Navigation Links
SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
Date:5/24/2013

SAN DIEGO, May 24, 2013 /PRNewswire/ -- Senomyx, Inc. (NASDAQ: SNMX), a  company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients, announced today that David Linemeyer , Ph.D., the Company's Vice President, Biology and Gwen Rosenberg , Vice President, Investor Relations & Corporate Communications, will present an overview of Senomyx's technology and programs on Friday, May 31, at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during the Citi 2013 Global Consumer Conference.  The conference is taking place at the Hilton New York Hotel in New York, NY.  During the presentation, Dr. Linemeyer and Ms. Rosenberg will discuss corporate developments including the Company's pipeline of novel flavor ingredients and its business strategy.

To access the live presentation or a subsequent archived recording, please log onto Senomyx's website at http://www.senomyx.com and click on the "Investor Relations" tab.  The archived webcast will be available for 30 days following the presentation.  Please connect to Senomyx's website prior to the start of the webcast to ensure adequate time to download any software that may be necessary.

About Senomyx, Inc. (www.senomyx.com)
Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
2. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
4. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
5. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
7. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
8. [Webcast] RateMyProduct, Product Assessment Tool for Life Science Suppliers
9. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
10. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
11. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... WAYNE, Pa., May 15 Escalon Medical Corp.,(Nasdaq: ... quarter and,nine months ended March 31, 2008., For ... 18% to,$8,139,000 compared with $6,900,000 reported in the same ... sales in each of the,Company,s business units., Net ...
... biotechnology company that is focused on the development of,autologous (patient-derived) ... heart damage, today announced financial results for,the quarter ended March ... 19, 2008, the Company completed its initial public offering ... of approximately $5.8 million. The net ...
... Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends strategies, ... Inc. and,the International Expert Wound Care Advisory Panel ... Improve Pressure,Ulcer Prevention and Treatment: Implications of the ...
Cached Biology Technology:Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8Bioheart, Inc. Announces Financial Results for First Quarter 2008 2Bioheart, Inc. Announces Financial Results for First Quarter 2008 3Bioheart, Inc. Announces Financial Results for First Quarter 2008 4Bioheart, Inc. Announces Financial Results for First Quarter 2008 5Bioheart, Inc. Announces Financial Results for First Quarter 2008 6Bioheart, Inc. Announces Financial Results for First Quarter 2008 7International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... acne (Propionibacterium acnes) will be the topic of the Denver ... University. As well as acne, this bacterium is responsible for ... diagnosis. Why are we not more aware of this versatile ... and boost the immune system: , Probiotics can ...
... Most college students in the United States do ... an essential skill in understanding the causes and ... the January issue of BioScience . The ... from Michigan State University, calls for a new way ...
... Scientists at Rothamsted Research, United Kingdom, in collaboration with ... Areas (ICARDA), Syria have developed a method of accounting ... trend refers to the variations in crop yield and ... trial. Usually plant breeders will grow several replicate ...
Cached Biology News:Probiotics, prebiotics and biofuel-producing bacteria 2College students lack scientific literacy, study finds 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Protein size: 325 Accession ... using peptide based assay: 1:1562500 ... 1.0g/ml in 5% skim milk / ... should be diluted in 1: 50,000 - ...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Active GST Protein...
Biology Products: